Literature DB >> 15277232

Cathepsin K is the principal protease in giant cell tumor of bone.

Jan H N Lindeman1, Roeland Hanemaaijer, Adri Mulder, P D Sander Dijkstra, Károly Szuhai, Dieter Bromme, Jan H Verheijen, Pancras C W Hogendoorn.   

Abstract

Giant cell tumor (GCT) of bone is a neoplasm of bone characterized by a localized osteolytic lesion. The nature of GCT is an enigma and the cell type(s) and protease(s) responsible for the extensive localized clinicoradiological osteolysis remain unresolved. We evaluated protease expression and cellular distribution of the proteolytic machinery responsible for the osteolysis. mRNA profiles showed that cathepsin K, cathepsin L, and matrix metalloproteinase (MMP)-9 were the preferentially expressed collagenases. Moderate expression was found for MMP-13, MMP-14, and cathepsin S. Specific protease activity assays revealed high cathepsin K activity but showed that MMP-9 was primarily present (98%) as inactive proenzyme. Activities of MMP-13 and MMP-14 were low. Immunohistochemistry revealed a clear spatial distribution: cathepsin K, its associated proton pump V-H(+)-ATPase, and MMP-9 were exclusively expressed in osteoclast-like giant cells, whereas cathepsin L expression was confined to mononuclear cells. To explore a possible role of cathepsin L in osteolysis, GCT-derived, cathepsin L-expressing, mononuclear cells were cultured on dentine disks. No evidence of osteolysis by these cells was found. These results implicate cathepsin K as the principal protease in GCT and suggest that osteoclast-like giant cells are responsible for the osteolysis. Inhibition of cathepsin K or its associated proton-pump may provide new therapeutic opportunities for GCT.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15277232      PMCID: PMC1618565          DOI: 10.1016/S0002-9440(10)63323-8

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  30 in total

Review 1.  The nature of giant cell tumor of bone.

Authors:  M Wülling; C Engels; N Jesse; M Werner; G Delling; E Kaiser
Journal:  J Cancer Res Clin Oncol       Date:  2001-08       Impact factor: 4.553

2.  Localization of cathepsin K in human osteoclasts by in situ hybridization and immunohistochemistry.

Authors:  A Littlewood-Evans; T Kokubo; O Ishibashi; T Inaoka; B Wlodarski; J A Gallagher; G Bilbe
Journal:  Bone       Date:  1997-02       Impact factor: 4.398

3.  Quantification of the expression levels of lysosomal cysteine proteinases in purified human osteoclastic cells by competitive RT-PCR.

Authors:  O Ishibashi; T Inui; Y Mori; T Kurokawa; T Kokubo; M Kumegawa
Journal:  Calcif Tissue Int       Date:  2001-02       Impact factor: 4.333

4.  Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization.

Authors:  M Gowen; F Lazner; R Dodds; R Kapadia; J Feild; M Tavaria; I Bertoncello; F Drake; S Zavarselk; I Tellis; P Hertzog; C Debouck; I Kola
Journal:  J Bone Miner Res       Date:  1999-10       Impact factor: 6.741

Review 5.  The histogenesis of giant cell tumour of bone: a model of interaction between neoplastic cells and osteoclasts.

Authors:  M H Zheng; P Robbins; J Xu; L Huang; D J Wood; J M Papadimitriou
Journal:  Histol Histopathol       Date:  2001-01       Impact factor: 2.303

6.  Cysteine proteinases in chondrosarcomas.

Authors:  M Söderström; T Ekfors; T Böhling; A Aho; H T Aro; E Vuorio
Journal:  Matrix Biol       Date:  2001-01       Impact factor: 11.583

7.  Accelerated turnover of metaphyseal trabecular bone in mice overexpressing cathepsin K.

Authors:  R Kiviranta; J Morko; H Uusitalo; H T Aro; E Vuorio; J Rantakokko
Journal:  J Bone Miner Res       Date:  2001-08       Impact factor: 6.741

8.  Potent and selective cathepsin L inhibitors do not inhibit human osteoclast resorption in vitro.

Authors:  I E James; R W Marquis; S M Blake; S M Hwang; C J Gress; Y Ru; D Zembryki; D S Yamashita; M S McQueney; T A Tomaszek; H J Oh; M Gowen; D F Veber; M W Lark
Journal:  J Biol Chem       Date:  2001-01-08       Impact factor: 5.157

9.  Cathepsin K expression in human lung.

Authors:  F Bühling; N Waldburg; A Gerber; C Häckel; S Krüger; D Reinhold; D Brömme; E Weber; S Ansorge; T Welte
Journal:  Adv Exp Med Biol       Date:  2000       Impact factor: 2.622

Review 10.  Novel bone antiresorptive agents that selectively inhibit the osteoclast V-H+-ATPase.

Authors:  C Farina; S Gagliardi; G Nadler; M Morvan; C Parini; P Belfiore; L Visentin; M Gowen
Journal:  Farmaco       Date:  2001 Jan-Feb
View more
  33 in total

1.  Collagenase expression and activity in the stromal cells from giant cell tumour of bone.

Authors:  Robert W Cowan; Isabella W Y Mak; Nigel Colterjohn; Gurmit Singh; Michelle Ghert
Journal:  Bone       Date:  2009-02-12       Impact factor: 4.398

2.  Histogenetic characterization of giant cell tumor of bone.

Authors:  Manuela Salerno; Sofia Avnet; Marco Alberghini; Armando Giunti; Nicola Baldini
Journal:  Clin Orthop Relat Res       Date:  2008-06-10       Impact factor: 4.176

3.  Morphological and immunophenotypic features of primary and metastatic giant cell tumour of bone.

Authors:  M Alberghini; K Kliskey; T Krenacs; P Picci; L Kindblom; R Forsyth; N A Athanasou
Journal:  Virchows Arch       Date:  2009-12-15       Impact factor: 4.064

4.  Cathepsin B inhibition limits bone metastasis in breast cancer.

Authors:  Nimali P Withana; Galia Blum; Mansoureh Sameni; Clare Slaney; Arulselvi Anbalagan; Mary B Olive; Bradley N Bidwell; Laura Edgington; Ling Wang; Kamiar Moin; Bonnie F Sloane; Robin L Anderson; Matthew S Bogyo; Belinda S Parker
Journal:  Cancer Res       Date:  2012-01-19       Impact factor: 12.701

Review 5.  Integration of denosumab therapy in the management of giant cell tumors of bone.

Authors:  Daniel T Miles; Ryan T Voskuil; Wood Dale; Joel L Mayerson; Thomas J Scharschmidt
Journal:  J Orthop       Date:  2020-03-28

Review 6.  The clinical approach toward giant cell tumor of bone.

Authors:  Lizz van der Heijden; P D Sander Dijkstra; Michiel A J van de Sande; Judith R Kroep; Remi A Nout; Carla S P van Rijswijk; Judith V M G Bovée; Pancras C W Hogendoorn; Hans Gelderblom
Journal:  Oncologist       Date:  2014-04-09

7.  Pycnodysostosis: Novel Variants in CTSK and Occurrence of Giant Cell Tumor.

Authors:  Arya Shambhavi; Smrithi Salian; Hitesh Shah; Mohandas Nair; Krishna Sharan; Dong-Kyu Jin; Sung Yoon Cho; Mary Mathew; Anju Shukla; Katta M Girisha
Journal:  J Pediatr Genet       Date:  2017-07-13

8.  Ablation of cathepsin k activity in the young mouse causes hypermineralization of long bone and growth plates.

Authors:  Adele L Boskey; Bruce D Gelb; Eric Pourmand; Valery Kudrashov; Stephen B Doty; Lyudmila Spevak; Mitchell B Schaffler
Journal:  Calcif Tissue Int       Date:  2009-01-27       Impact factor: 4.333

9.  A broad survey of cathepsin K immunoreactivity in human neoplasms.

Authors:  Gang Zheng; Guido Martignoni; Cristina Antonescu; Elizabeth Montgomery; Charles Eberhart; George Netto; Janis Taube; William Westra; Jonathan I Epstein; Tamara Lotan; Anirban Maitra; Edward Gabrielson; Michael Torbenson; Christine Iacobuzio-Donahue; Angelo Demarzo; Ie Ming Shih; Peter Illei; T C Wu; Pedram Argani
Journal:  Am J Clin Pathol       Date:  2013-02       Impact factor: 2.493

Review 10.  Cathepsin K inhibitors for osteoporosis and potential off-target effects.

Authors:  Dieter Brömme; Fabien Lecaille
Journal:  Expert Opin Investig Drugs       Date:  2009-05       Impact factor: 6.206

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.